Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions

被引:0
|
作者
Yao, Yingsha [1 ]
Shi, Liujing [1 ]
Zhu, Xiaoming [1 ,2 ]
机构
[1] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
[2] Zhejiang Univ, Womens Hosp, Sch Med, Key Lab Womens Reprod Hlth Zhejiang Prov, Hangzhou 310006, Peoples R China
关键词
polycystic ovary syndrome; endometrial proliferative lesions; anti-Mullerian hormone; threshold value; regression model; POLYCYSTIC-OVARY-SYNDROME; CANCER STATISTICS; RISK; HYPERPLASIA; ULTRASOUND; PREDICTION; CONSENSUS; CRITERIA; CA125; HE-4;
D O I
10.3390/diagnostics13213301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20-39 years, the most effective screening threshold for AMH was found to be a serum AMH level of <= 5.39 ng/mL. The model used for this group was logit(p) = -2.562 - 0.430 x AMH + 0.127 x BMI + 1.512 x hypertension + 0.956 x diabetes -1.145 x regular menstruation. On the other hand, for non-PCOS women aged 20-39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of <= 2.18 ng/mL. The model used for this group was logit(p) = -3.778 - 0.823 x AMH + 0.176 x BMI + 2.660 x diabetes -1.527 x regular menstruation -1.117 x dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20-39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] ANTI-MULLERIAN HORMONE
    JOSSO, N
    BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1991, 5 (04): : 635 - 654
  • [32] The effects of orchiopexy on serum anti-Mullerian hormone levels in unilateral cryptorchid infants
    Demircan, M
    Akinci, A
    Mutus, M
    PEDIATRIC SURGERY INTERNATIONAL, 2006, 22 (03) : 271 - 273
  • [33] Serum anti-Mullerian hormone levels and insulin resistance in polycystic ovary syndrome
    Makhlouf, R.
    Chaabouni, K.
    Charfi, A.
    Jallouli, D.
    Elleuch, A.
    Ayedi, F.
    CLINICA CHIMICA ACTA, 2022, 530 : S129 - S129
  • [34] Anti-Mullerian hormone levels in serum 1 year after unilateral orchiopexy
    Komarowska, Marta Diana
    Hermanowicz, Adam
    Matuszczak, Ewa
    Oksiuta, Marzanna
    Dzienis-Koronkiewicz, Ewa
    Zelazowska-Rutkowska, Beata
    Debek, Wojciech
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2012, 25 (11-12): : 1073 - 1076
  • [35] ANTI-MULLERIAN HORMONE
    JOSSO, N
    PICARD, JY
    PHYSIOLOGICAL REVIEWS, 1986, 66 (04) : 1038 - 1090
  • [36] Anti-Mullerian Hormone Concentrations in Premenopausal Women and Breast Cancer Risk
    Nichols, Hazel B.
    Baird, Donna D.
    Stanczyk, Frank Z.
    Steiner, Anne Z.
    Troester, Melissa A.
    Whitworth, Kristina W.
    Sandler, Dale P.
    CANCER PREVENTION RESEARCH, 2015, 8 (06) : 528 - 534
  • [37] Repetitive oocyte donation does not decrease serum anti-Mullerian hormone levels
    Bukulmez, Orhan
    Li, Qin
    Carr, Bruce R.
    Leader, Benjamin
    Doody, Kathleen M.
    Doody, Kevin J.
    FERTILITY AND STERILITY, 2010, 94 (03) : 905 - 912
  • [38] ANTI-MULLERIAN HORMONE
    JOSSO, N
    RECHERCHE, 1978, 9 (88): : 379 - 381
  • [39] Testosterone and androstenedione are positively associated with anti-Mullerian hormone in premenopausal women
    Islam, Rakibul M.
    Bell, Robin J.
    Skiba, Marina A.
    Davis, Susan R.
    CLINICAL ENDOCRINOLOGY, 2021, 95 (05) : 752 - 759
  • [40] Anti-mullerian hormone levels are associated with live birth rates in ART, but the predictive ability of anti-mullerian hormone is modest
    Alson, Sara S. E.
    Bungum, Leif J.
    Giwercman, Aleksander
    Henic, Emir
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2018, 225 : 199 - 204